News >

Pembrolizumab Active in Thymic Carcinoma

Jason Harris
Published: Thursday, Feb 22, 2018

Giuseppe Giaccone, MD, PhD

Giuseppe Giaccone, MD, PhD
Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy, according to findings from a phase II trial published in The Lancet Oncology.

Investigators noted that 6 patients (15%) developed at least 1 new-onset severe immune-related adverse event (irAE). Four of these patients were treated with 125 mg of methylprednisolone followed by 1 to 2 mg/kg of prednisone daily or 4 mg of dexamethasone every 4 hours. Four patients were hospitalized, but no patient with severe irAEs died because of toxicity. Three patients with severe irAEs required dose interruptions.
Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study [published online January 26, 2018]. Lancet Oncol. doi: 10.1016/S1470-2045(18)30062-7.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication